Reaktionsgleichung
Br[C:2]1[C:16]([CH3:17])=[CH:15][C:5]([O:6][CH2:7][C:8]2([OH:14])[CH2:13][CH2:12][O:11][CH2:10][CH2:9]2)=[CH:4][C:3]=1[CH3:18].Br[C:20]1[CH:28]=[CH:27][C:26]([F:29])=[C:25]2[C:21]=1[CH2:22][CH2:23][C@H:24]2[O:30][C:31]1[CH:44]=[CH:43][C:34]2[C@H:35]([CH2:38][C:39]([O:41][CH3:42])=[O:40])[CH2:36][O:37][C:33]=2[CH:32]=1>>[F:29][C:26]1[CH:27]=[CH:28][C:20]([C:2]2[C:16]([CH3:17])=[CH:15][C:5]([O:6][CH2:7][C:8]3([OH:14])[CH2:13][CH2:12][O:11][CH2:10][CH2:9]3)=[CH:4][C:3]=2[CH3:18])=[C:21]2[C:25]=1[C@H:24]([O:30][C:31]1[CH:44]=[CH:43][C:34]3[C@H:35]([CH2:38][C:39]([O:41][CH3:42])=[O:40])[CH2:36][O:37][C:33]=3[CH:32]=1)[CH2:23][CH2:22]2Komponenten
3
Edukt 2
Produkt 1
Versuchsvorschrift
The title compound is prepared from methyl methyl 2-((S)-6-((R)-7-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,3-dihydro-1H-inden-1-yloxy)-2,3-dihydrobenzofuran-3-yl)acetate and 4-((4-bromo-3,5-dimethylphenoxy)methyl)tetrahydro-2H-pyran-4-ol following a procedure analogous to that described in Step 5 of Intermediate 1. The product is purified by HPLC on reversed phase. LC (method 7): tR=1.17 min; Mass spectrum (ESI+): m/z=577 [M+H]+.
Aufarbeitung
- customThe product is purified by HPLC on reversed phase
Quellen und Nachweise
- ORD-Eintrag
- ord-a47c2c65dd8a40f98c66f7bdd074ac26
- Quelldatensatz
- uspto-grants-2014_02
- Patentnummer
- US08642585B2
Verknüpfte Notizen
Wird geladen…